BRAF and synovial sarcoma: ,43 This rarity of this mutation in SS posed two challenging questions for the personalized medicine: whether BRAF inhibitors (including vemurafenib [Vem] and dabrafenib), known for efficacy in BRAFV600E melanoma, could be applied to treat SS and which inhibitor should be chosen.44